<DOC>
	<DOCNO>NCT01808352</DOCNO>
	<brief_summary>Black men sex men ( MSM ) Pre-Exposure Prophylaxis ( PrEP ) Study Client Centered Care Coordination ( C4 ) Component .</brief_summary>
	<brief_title>HPTN 073 Black Men Who Have Sex With Men ( MSM ) Pre-Exposure Prophylaxis ( PrEP )</brief_title>
	<detailed_description>An open label demonstration study PrEP Client Centered Care Coordination ( C4 ) ass initiation , acceptability , safety , feasibility PrEP Black MSM ( BMSM ) three US Cities . A subset participant also recruit participate qualitative interview facilitator barrier regard PrEP . The study recruit HIV-uninfected BMSM risk HIV infection three US Cities . Enrollment include age 18 effort recruit equal number BMSM age 25 age 25 total 225 participant ( 75 per site ) .</detailed_description>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>BMSM meet follow criterion eligible inclusion study : 18 year age old No prior HIV diagnosis ( selfreport ) Male birth High risk acquire HIV infection include one follow previous 6 month : Unprotected sex receptive insertive anal intercourse male partner Any protect unprotected : . Receptive insertive anal intercourse three male sex partner ii . Exchange money , gift , shelter drug receptive insertive anal sex male partner iii . Receptive insertive anal sex influence drug alcohol ( i.e. , high drunk within two hour sex act ) accord selfreport '' STI diagnosis ( i.e. , syphilis , gonorrhea chlamydia ) selfreport Willing provide locator information accordance Study Specific Procedures ( SSP ) Manual Urine dipstick negative trace protein glucose Hemoglobin &gt; 11 g/dL , absolute neutrophil count &gt; 750 cells/mm3 , platelet count ≥ 100,000/mm3 Serum creatinine &lt; upper limit normal ( ULN ) calculate creatinine clearance least 60 mL/min CockcroftGault formula : eCcr mL/min = [ ( 140 age year ) x ( actual body weight kg ) ] / ( 72 x serum creatinine mg/dL ) Alanine aminotransferase ( AST ) aspartate aminotransferase ( ALT ) &lt; 3 time upper limit normal ( ULN ) Total bilirubin &lt; 2.5 ULN Hepatitis B surface antigen ( HBsAg ) negative BMSM meet follow criterion exclude study : Any reactive positive HIV test Screening , even subsequent test indicate person HIVuninfected Transgender Active chronic hepatitis B infection ( evidenced HBsAg , HbsAb , HbcAb test ) Planning move area travel 3 month study followup period Unwilling adhere study procedure Current participation research study via selfreport ( however , strictly nonHIV center observational study exclusionary ) Previous participation HIV vaccine study exclusionary unless documented evidence enrollment placebo arm Use ARV drug ( PrEP PEP ) last 60 day Prior history gastrectomy , colostomy , ileostomy , procedure alter gastrointestinal tract drug absorption ( provide selfreport , obtain medical history record ) Receipt prohibit medication : interleukin therapy , medication significant nephrotoxic potential ( include limit amphotericin B , aminoglycosides , cidofovir , foscarnet systemic chemotherapy ) , medication may inhibit compete elimination via active renal tubular secretion ( include limit probenecid ) ( provide selfreport , obtain medical history medical record ) Any condition , opinion study staff , would make participation study unsafe , interfere achieve study objective</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>AE adverse event</keyword>
	<keyword>AIDS acquire immunodeficiency syndrome</keyword>
	<keyword>ALT ( SGPT ) alanine aminotransferase</keyword>
	<keyword>ART antiretroviral therapy</keyword>
	<keyword>AST ( SGOT ) aspartate aminotransferase</keyword>
	<keyword>DCF data collection form</keyword>
	<keyword>DMC Data Monitoring Committee</keyword>
	<keyword>FDA ( U.S. ) Food Drug Administration</keyword>
	<keyword>GCP Good Clinical Practice guideline</keyword>
	<keyword>HB sAg Hepatitis B surface antigen</keyword>
	<keyword>ICH International Conference Harmonisation</keyword>
	<keyword>IND Investigational New Drug Application</keyword>
	<keyword>IRB Institutional Review Board</keyword>
	<keyword>IU International unit</keyword>
	<keyword>mg milligram ( )</keyword>
	<keyword>mm3 cubic millimeter ( )</keyword>
	<keyword>PCR polymerase chain reaction</keyword>
	<keyword>SAE serious adverse event</keyword>
	<keyword>µg microgram</keyword>
	<keyword>ULN upper limit normal range</keyword>
	<keyword>WB Western Blot</keyword>
</DOC>